Pfizer loses appeal over co-pay help for $225,000 per year heart drug
The Second Circuit appeals court on Monday sided with the HHS inspector general and confirmed a district court’s decision that Pfizer cannot help patients with their co-pays for its $225,000 per year heart drug without violating a federal anti-kickback law.
The drug, known as tafamidis, treats a rare, progressive heart condition known as transthyretin amyloid cardiomyopathy. An estimated 100,000 to 150,000 Americans, most of whom are elderly, suffer from the condition, according to the opinion.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
